Table 5 Clinical parameter outcomes from the two groups in older adults with stage 3–5 CKD
Intervention group (n = 24) | Control group (n = 23) | P- valueb | |||||
|---|---|---|---|---|---|---|---|
Baseline | 3 months | Change in value (3 months-Baseline)a | Baseline | 3 months | Change in value (3 months-Baseline)a | ||
BUN (mg/dl) | 31 (25–43) | 29 (22–43) | -2 (-6- -1)† | 31 (23–46) | 26 (19–53) | -2 (-5–1) | 0.75 |
eGFR (mL/min per/1.73 m2) | |||||||
MDRD | 36 (19–45) | 38 (16–44) | -1 (-3–3) | 34 (22–50) | 31 (19–50) | -1 (-4–1) | 0.51 |
CKD-EPI (2009) | 31 (16–42) | 34 (14–39) | -1 (-3–2) | 32 (20–46) | 28 (17–46) | 0 (-4–1) | 0.78 |
CKD-EPI (2021) | 34 (18–46) | 37 (15–43) | -1 (-3–3) | 34 (22–50) | 30 (19–50) | -4 (-1–1) | 0.78 |
Creatinine (mg/dl) | 1.7 (1.6–3.4) | 1.7 (1.5–3.7) | 0.0 (-0.1–0.3) | 1.9 (1.4–3.0) | 1.9 (1.4–3.4) | 0.1 (-0.1–0.3) | 0.35 |
LDL (mg/dL) | 89 (77–124) | 94 (73–134) | -2 (-14–13) | 88 (72–115) | 82 (70–114) | -2 (-17–10) | 0.82 |
Triglyceride (mg/dl) | 108 (83–164) | 120 (77–194) | 7 (-12–32) | 111 (74–146) | 119 (79–143) | 0 (-20–22) | 0.20 |
Albumin (g/dl) | 4.2 (4.1–4.4) | 4.2 (4.1–4.3) | 0.0 (-0.2–0.1) | 4.2 (3.9–4.4) | 4.2 (3.8–4.4) | 0.0 (-0.2–0.1) | 0.92 |
Hemoglobin (g/dl) | 11.8 (10.2–13.7) | 12.2 (10.5–13.7) | 0.0 (-0.7–0.7) | 12.3 (9.8–13.7) | 12.1 (9.6–14.0) | -0.4 (-0.9–0.3) | 0.30 |
ALT (U/L) | 18.5 (12.3–21.0) | 17.5 (11.3–21.0) | -1.0 (-5.0–2.8) | 18.0 (14.0–24.0) | 17.0 (14.0–31.8) | 0.0 (-3.0–3.5) | 0.43 |